A. Fernández-Medarde
Molecular Biology · 2011–2015
A researcher in the Science corpus: 2 papers; trusts 5 researchers and is trusted by 0 researchers here, as inferred from the citation graph.
Subfields
- Molecular Biology — 63 citations into it
- Biomaterials — 50 citations into it
- Biomedical Engineering — 33 citations into it
- Oncology — 28 citations into it
- Organic Chemistry — 6 citations into it
Whom A. Fernández-Medarde trusts overall
Their strongest outbound trust, strongest first, inferred from their citations.
Who trusts A. Fernández-Medarde overall
Papers from A. Fernández-Medarde's perspective
Ordered by how strongly the researchers A. Fernández-Medarde trusts endorse each paper. Same corpus, a different order for every researcher.
- Ligand-targeted therapeutics in anticancer therapy (Nature Reviews. Cancer)
- Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF.
- Recent advances with liposomes as pharmaceutical carriers (Nature reviews. Drug discovery)
- Nanoparticles for drug delivery in cancer treatment. (Urologic oncology)
- Active targeting schemes for nanoparticle systems in cancer therapeutics. (Advanced Drug Delivery Reviews)
- Cancer nanotechnology: opportunities and challenges (Nature Reviews. Cancer)
- Drug Delivery Systems: Entering the Mainstream (Science)
- Tumor vascular permeability, accumulation, and penetration of macromolecular drug carriers. (Journal of the National Cancer Institute)
- Polymer conjugates as anticancer nanomedicines (Nature Reviews. Cancer)
- Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models. (Cancer Research)
Their papers
- Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy. (2015) — 1,606 citations
- Ras in cancer and developmental diseases. (2011) — 849 citations